Skip to main content
SpringerLink
Log in
Book cover

Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics pp 445–456Cite as

Tigecycline

  • Chapter
  • First Online:

  • 3357 Accesses

Abstract

Tigecycline is a glycylcycline antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, atypical, anaerobic and multidrug resistant organisms. Tigecycline displays linear pharmacokinetics with widespread tissue distribution into both infected and non-infected tissue and non-linear protein binding. Tigecycline has a half-life between 40-60 hours and is mostly eliminated unchanged as parent drug in the feces, with minor elimination via the urine. Free-drug AUC:MIC ratio is the PK-PD index most closely associated with the efficacy of tigecycline. Dosing of tigecycline does not need to be adjusted for those patients with renal insufficiency. However, those patients with severely decompensated cirrhosis of the liver may require a dosing adjustment. The most commonly reported adverse events associated with the use of tigecycline include nausea and vomiting and are linked to high 24 hour AUC values.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse EJ (2009) Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 63:38–42

    Article  CAS  PubMed  Google Scholar 

  • Andes DR, Craig WA (2007) Pharmacokinetic and pharmacodynamics of tetracyclines. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (eds) Antimicrobial pharmacodynamics in theory and clinical practice. Informa Healthcare USA, New York

    Google Scholar 

  • Bhavnani SM, Rubino CM, Ambrose PG, Babinchak TJ, Korth-Bradley JM, Drusano GL (2010) Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob Agents Chemother 54:1207–1212

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bhavnani SM, Rubino CM, Hammel J, Forrest A, Dukart G, Dartois N, Cooper A, Korth-Bradley J, Ambrose PG (2012) Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treat with tigecycline. Antimicrob Agents Chemother 56(2):1065–1072

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bulik CC, Wiskirchen DE, Shepard A, Sutherland CA, Kuti JL, Nicolau DP (2010) Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 54:5209–5213

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232–260

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Crandon JL, Banevicius MA, Nicolau DP (2009a) Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother 53:1165–1169

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Crandon JL, Kim A, Nicolau DP (2009b) Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother 64:837–839

    Article  CAS  PubMed  Google Scholar 

  • Hoellman DB, Pankuch GA, Jacobs MR, Appelbaum PC (2000) Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 44:1085–1088

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hoffman M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J, Scatina J (2007) Metabolism, excretion, and pharmacokinetics of [14C]Tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 35:1543–1553

    Article  Google Scholar 

  • Huang V, Cheung CM, Kaatz GW, Rybak MJ (2010) Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 35:25–29

    Article  CAS  PubMed  Google Scholar 

  • Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP (2009a) Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 53:5060–5063

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Koomanachai P, Kim A, Nicolau DP (2009b) Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother 63:982–987

    Article  CAS  PubMed  Google Scholar 

  • Korth-Bradley JM, Baird-Bellaire SJ, Patat AA, Troy SM, Böhmer GM, Gleiter CH, Buecheler R, Morgan MY (2011) Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol 51:93–101

    Article  CAS  PubMed  Google Scholar 

  • Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG (2007) Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 51:1939–1945

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mouton JW, Ambrose PG, Kalhmeter G, Wikler M, Craig WA (2007) Applying pharmacodynamics for susceptibility breakpoint selection and susceptibility testing. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (eds) Antimicrobial pharmacodynamics in theory and clinical practice. Informa Healthcare USA, New York

    Google Scholar 

  • Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S (2005) Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49:220–229

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nicasio AM, Crandon JL, Nicolau DP (2009) In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 53:2756–2761

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Passarell JA, Meagher AK, Liolios K et al (2005) Pharmacokinetic/pharmacodynamic model for the tolerability of tigecycline in healthy volunteers. In: 15th European congress of clinical microbiology and infectious diseases, Abstr P894

    Google Scholar 

  • Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG (2008) Exposure-response analysis of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 52:204–210

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Pichardo C, Pachón-Ibañez ME, Docobo-Perez F, López-Rojas R, Jiménez-Mejías ME, Garcia-Curiel A (2010) J Pachon. Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. Eur J Clin Microbiol Infect Dis 29:527–531

    Article  CAS  PubMed  Google Scholar 

  • Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ (2006) Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. Antimicrob Agents Chemother 58:1221–1229

    CAS  Google Scholar 

  • Rubino CM, Bhavnani SM, Forrest A, Dukart G, Dartois N, Cooper A, Korth-Bradley JM, Ambrose PG (2012) Tigecycline pharmacokinetics-pharmacodynamics in patients with community-acquired pneumonia. Antimicrob Agents Chemother 56(1):130–136

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Salvatore CM, Techasaensiri C, Taqliabue C, Katz K, Leos N, Gomez AM, McCracken GH, Hardy RD (2009) Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines ans chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 53:1546–1551

    Google Scholar 

  • Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA (2007) In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:1621–1626

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, Nicolau DP (2005) Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 49:1629–1632

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tombs NL (1999) Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. In: 39th Interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, 26–29 Sept 1999

    Google Scholar 

  • Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D (2003) The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). In: 43rd Interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, 14–17 Sept 2003

    Google Scholar 

  • van Ogtrop ML, Andes D, Stamstad TJ, Conklin B, Weiss WJ, Craig WA, Vesga O (2000) In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 44:943–949

    Article  PubMed Central  PubMed  Google Scholar 

  • van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Ciricione BB (2006) Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal of skin and skin structure infections. Antimicrob Agents Chemother 50:3701–3707

    Article  PubMed Central  PubMed  Google Scholar 

  • Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ (2004) The glycylcyclines. A comparative review with the tetracyclines. Drugs 64:63–88

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Clinical Pharmacodynamics, 43 British American Blvd, Latham, NY, 12110, USA

    Catharine C. Bulik Pharm.D. & Paul G. Ambrose Pharm.D., F.I.D.S.A.

  2. Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY, 12208, USA

    Anthony M. Nicasio Pharm.D.

Authors
  1. Catharine C. Bulik Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony M. Nicasio Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul G. Ambrose Pharm.D., F.I.D.S.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catharine C. Bulik Pharm.D. .

Editor information

Editors and Affiliations

  1. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

    Alexander A. Vinks

  2. Dept. Pharmaceutics, University of Florida, Gainesville College of Pharmacy, Gainesville, Florida, USA

    Hartmut Derendorf

  3. Dept. of Medical Microbiology, Radboudumc, Radboud University Nijmegen, Nijmegen, The Netherlands

    Johan W. Mouton

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bulik, C.C., Nicasio, A.M., Ambrose, P.G. (2014). Tigecycline. In: Vinks, A., Derendorf, H., Mouton, J. (eds) Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75613-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75613-4_17

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-75612-7

  • Online ISBN: 978-0-387-75613-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation